Volume 17, Number 6—June 2011
Dispatch
Outcome Predictors in Treatment of Yaws
Oriol Mitjà
, Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique Bassat
, Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique BassatTable 1
Demographic data, clinical signs/symptoms, laboratory results, and outcome after treatment of yaws in 138 case-patients, Papua New Guinea, January–September, 2009*
| Characteristic | Total no. (%) patients, N = 138 |
|---|---|
| Mean age, y (SD) | 9.6 (4.4) |
| Male sex |
81 (58.7) |
| VDRL titer | |
| 16 | 54 (39.1) |
| 32 | 33 (23.9) |
| 64 | 42 (30.4) |
| 128 |
9 (6.5) |
| Primary skin lesion | 81 (58.7) |
| Secondary stage |
63 (45.7)† |
| Family history |
36 (26.1) |
| Treatment with IM penicillin G benzathine | 138 (100.0) |
| Clinical healing | 132 (95.7) |
| Concurrent disease | 7 (5.1)‡ |
| Seroconversion | 63 (45.7) |
| Serologically defined treatment failure | 24 (17.4) |
*VDRL, Venereal Disease Research Laboratory; IM, intramuscular.
†Includes 7 cases of early yaws osteoperiostitis, among whom were 3 patients with dactylilitis.
‡Includes 3 cases of Plasmodium falciparum malaria, 1 case of P. vivax malaria, 1 case of acute diarrhea diagnosed at the 12-month follow-up visit, and 2 case-patients with a chronic underlying disease (1 case of congenital heart disease and 1 case of chronic asthma).
